ENZY Enzymotec Ltd. - Ordinary Shares (delisted)

This statement relates to Ordinary Shares NIS 0.01 par value per share of Enzymotec Ltd. (the “ Issuer ”), an Israeli corporation. The principle executive offices of the Issuer are located at Sagi 2000 Industrial Area, Migdal Ha’Emeq, 2310001, Israel .

The aggregate purchase price of the 1,732,742 ordinary shares, par value NIS 0.01 per share (the “ Shares ”) of the Issuer purchased to date by Frutarom is US$12,878,801.64 (an average price per share of US$7.43). The source of funding for the purchase of the Shares was the working capital of Frutarom.

The Reporting Persons purchased the Shares reported herein based on the Reporting Persons’ belief that the Shares represent a relevant investment opportunity and the Reporting Peron’s estimation that part of the Issuer’s portfolio is complementary to the Reporting Persons core of businesses. Depending upon overall market and general economic conditions, other investment opportunities available to the Reporting Persons, the market prices of the Shares, the business affairs and strategy and financial condition of the Issuer and other factors deemed relevant to the Reporting Persons, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares in the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable.

It is anticipated that the Reporting Persons may, from time to time, have discussions with management, the board of directors, and other stockholders of the Issuer. The Reporting Persons intend to monitor and evaluate the Issuer’s business, corporate governance and financial performance. The Reporting Persons also may decide in the future to propose a transaction whereby all or a portion of the Issuer’s assets be sold.

None of the Reporting Persons currently has other plans or proposals that relate to or would result in any of the consequences listed in paragraphs (a) through (j) of Item 4 of the Special Instructions for complying with Schedule 13D except as set forth herein or such as would occur upon completion of the actions discussed above.

(a)-(b)        As of the date of this Schedule 13D, the Reporting Persons beneficially own and have shared power to vote and shared power of disposition over 1,732,742 shares of the Issuer. Based on a total of 22,899,235 ordinary shares outstanding as of March 31, 2017 .

(c)        Between May 5, 2017 and July 31, 2017 the Reporting Persons purchased 799,969 ordinary shares NIS 0.01 par value per share of the Issuer.

(d)        Except for the Reporting Persons, no other person is known to have the right to receive or the power to direct the receipt of dividends from, the receipt of dividends from, or the proceeds from the sale of, the Shares beneficially owned by the Reporting Persons.

(e)        Not Applicable.

The Reporting Persons do not have any contracts, arrangements, understandings, or relationships (legal or otherwise) with respect to any securities of the Issuer.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: July 31, 2017